Safety Efficacy Evidence Indication&Attributes Prescribing-information Previous Next Over A Decade of Improving Patient Outcomes ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK 17/01/2022 | Author: Boehringer Ingelheim ONTARGET: MICARDIS® (TELMISARTAN) As protective as Ramipril Document ID: PC-SA-101594 | Expiry Date: 15/05/2026 MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY RELATED CONTENT Read more PDF MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY PC-SA-101593 (April 2026 ) Download Opens in new tab Read more PDF MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY PC-SA-101596 (May 2026 ) Download Opens in new tab Home Cardiovascular | Therapeutic Area Telmisartan ONTARGET TRIAL: MICARDIS®80 (TELMISARTAN) REDUCTION IN COMPOSITE CV RISK
Read more PDF MICARDIS® (TELMISARTAN) HAS PLACEBO-LIKE TOLERABILITY PC-SA-101593 (April 2026 ) Download Opens in new tab
Read more PDF MICARDIS® (TELMISARTAN) REDUCES THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY PC-SA-101596 (May 2026 ) Download Opens in new tab
